SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalAMDL Inc.


Previous 10 Next 10 
To: John Boluyt who wrote (13)6/22/1996 10:25:00 PM
From: Eduardo Canto
   of 28
 
Mr. Boluyt,

Can't say if you did the right thing or not. I got in at $1 and don't plan to sell until we hit $3 which I don't think will take long. The company is beginning to get some good exposure and I believe there are still some reviews that haven't come out just yet. Their product should bring revenues in soon, particularly from China where the approval process for marketing I hear is moving along well. In addition, they are developing an H. Pylori test kit for which they are preparing to apply for FDA approval.

Good investing,
E.C.

Share RecommendKeepReplyMark as Last Read


To: Stock Puppy who wrote ()5/16/1997 5:41:00 PM
From: Stock Puppy
   of 28
 
Edgar report filed:
sec.gov

Share RecommendKeepReplyMark as Last Read


To: Stock Puppy who wrote ()6/3/1997 9:05:00 AM
From: Stock Puppy
   of 28
 
sec.yahoo.com

Share RecommendKeepReplyMark as Last Read


To: Stock Puppy who wrote ()7/25/1997 11:52:00 AM
From: Stock Puppy
   of 28
 
AMDL, Inc. Files Patent for Novel Cancer Diagnostic System

TUSTIN, Calif., July 24 /PRNewswire/ -- AMDL, Inc. (OTC Bulletin Board: AMDD) today announced that it has filed for patent protection for a novel immunoassay,
Oncochek(TM) which AMDL scientists have developed for the detection of a number of cancers. The assay uses a monoclonal antibody to an octopeptide, and a
polyclonal antibody to measure the level of fibrinogen degradation products, (FDP), in the serum of a cancer patient. FDP level in cancer patients is elevated due to an
increased secretion of protein degrading enzymes by the tumor cells.

Serum from incompletely clotted blood does not appear to cause any problems with the assay. As a result it is not as sensitive to the manner in which the serum sample
is collected, and is less prone to false positive readings. Preliminary findings indicate that FDP levels in serum of cancer patients are elevated. Such findings are
consistent with the widely accepted finding that growing tumors have an increased rate of protease release.

AMDL, Inc. is a biomedical company applying immunochemical technology to develop novel diagnostic tests for use in the diagnosis of cancer and other diseases.

NOTE: Certain statements in this announcement that relate to AMDL, Inc.'s plans, objectives or future performance may be deemed forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations. Actual strategies and results in
future periods may differ materially from those currently expected because of various risks and uncertainties. Additional discussion of factors affecting AMDL, Inc.'s
business and prospects is contained in its periodic filings with the Securities and Exchange Commission.

Share RecommendKeepReplyMark as Last Read


To: Stock Puppy who wrote ()8/1/1997 1:15:00 PM
From: Stock Puppy
   of 28
 
AMDL, INC. Announces the Initiation of Commercial Sales

TUSTIN, Calif., Aug. 1 /PRNewswire/ -- AMDL, Inc. (OTCBB:AMDD) today announced that it has received an initial order for its
DR-70 cancer diagnostic kit from China under the recently renegotiated distribution agreement. Sales have also begun in Brazil,
Malaysia and Poland. The orders represent modest income at this time, but mark an important milestone for AMDL in that it is the true
beginning of commercial sales for the company. We are anticipating a very nice ramping up as the company moves forward both with
other products and distributors around the world.

AMDL, Inc. is a biomedical company applying immunochemical technology to develop novel diagnostic tests for use in the diagnosis
of cancer and other diseases.

Note: Certain statements in this announcement that relate to AMDL, Inc.'s plans, objectives or future performance may be deemed
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based on
management's current expectations. Actual strategies and results in future periods may differ materially from those currently expected
because of various risks and uncertainties. Additional discussion of factors affecting AMDL, Inc.'s business and prospects is contained
in its periodic filings with the Securities and Exchange Commission.

Share RecommendKeepReplyMark as Last Read


To: Stock Puppy who wrote ()11/10/1997 10:15:00 AM
From: Stock Puppy
   of 28
 
Quarterly Report
0.01 loss vs 0.02 loss.
Nothing much new to report though.

sec.yahoo.com

Share RecommendKeepReplyMark as Last Read


To: Stock Puppy who wrote ()12/15/1997 9:41:00 AM
From: Stock Puppy
   of 28
 
Did anyone get a letter from AMDL Dr. Ngo promising to
"heighten shareholder value for all"?

(anyone here still have their AMDL stock ? :-)

Here is a summary of the letter...

Their tests in China, with small sample (136 patients,
many different types of cancer)
show 84% detection rate (compareds to competitors 60%)
and 5% false positive rate.They'll be seeking approval to
market in China after 300 patients have been tested.

AMDL also claims positive readings for lung cancer, irregardless
of the type. DR-70 is also elevated in lupus and hepatitis...

Share RecommendKeepReplyMark as Last Read


To: Stock Puppy who wrote ()1/6/1998 1:02:00 PM
From: Stock Puppy
   of 28
 
AMDL is now sending out a newsletter to investors.
At least Dr Ngo is keeping us informed...

Share RecommendKeepReplyMark as Last Read


To: Stock Puppy who wrote ()3/26/1998 8:23:00 AM
From: Alan S
   of 28
 
Anyone still following this company? I have been a shareholder for about 5 years and I've lost a bunch!! But I just grabbed 30000 shares cuz I think they are having an unjustified "fire sale". I think this really should be well over a dollar. They are done with testing and HAVE submitted to the China Gov for approval according to Tom Tilton who I talked to last week. Also, they are finishing testing in Calif to submit their ulcer test product to the US Gov for approval to sell. Tom says they are currently selling some of their other products so their sales are in the $10k range per month now which is a lot better than it's been. I'm banking BIG on this outfit. Anyone else know anything about them??

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: Alan S who wrote (22)4/2/1998 8:56:00 AM
From: Stock Puppy
   of 28
 
Two threads on this topic:
This one here and in
medical devices: AMDL Inc (OTC BB:AMDD) 18 month target $10
Subject 6085
there has been a flurry of discussion.
(I think the thread started well over 18 months ago :-))
I hope that this thread can discuss more serious aspects of AMDL
(Tho like most, I don't have much info)

Since you've posted to the other group, you know that some penny
stock newletter recommended this thing, so the price rise is probably more a reflection of that and the day traders than the news release:
"AMDL Cancer Screening Test Kit Determined Useful, Reliable in Detecting Cancer; Clinical Trials in China"
biz.yahoo.com

I think that the statement in the release :
"AMDL is in the process of submitting the results of the clinical trial to the Chinese Ministry of Health for approval to market its kit in the world's most populous nation. "
is key - until AMDL AMDL is able to do wholesale marketing of their
product, stock price is just speculation (playing which is where you
can lose or win big :-)). I believe that aceppted for clinical trials
in China doesn't mean much for USA market - there would still have to be clinical trials in the US and FDA aproval before marketing is allowed.

So, I guess the next questions are:
How long do clinical trials take? (in general...)
and for the China market,
is there the equivalent of FDA approval in China?

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10